Judith Haas

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Hans‐Peter Tony, Gerd R Burmester, Hendrik Schulze‐Koops et al. · Arthritis Research & Therapy · 2011 · 208 citations · Full text

Life Sciences, Dermatology, Immunology +16

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry

Paulus Rommer, David Ellenberger, Peter Flachenecker et al. · Multiple Sclerosis Journal · 2018 · 140 citations

Medicine, Neurology, Disability Management +14

A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

Judith Haas, O. R. Hommes · Multiple Sclerosis Journal · 2007 · 129 citations

Life Sciences, Immunology, Pharmacotherapy +10

Molecular mechanisms in down-regulation of tumor necrosis factor expression.

Judith Haas, Patrick A. Baeuerle, G. Riethmüller et al. · Proceedings of the National Academy of Sciences · 1990 · 116 citations

Life Sciences, Cell Biology, Immunology +16